Oil prices rise from over 1-mth low with Russia crude buyer sanctions in focus
LOS ANGELES - BioSig Technologies, Inc. (NASDAQ:BSGM), a medical technology company valued at approximately $110 million, has announced the appointment of Sean Roosen as Strategic Advisor to its subsidiary Streamex Exchange Corporation. The company’s stock has shown remarkable momentum, delivering over 355% returns in the past six months. According to InvestingPro analysis, the stock is currently trading above its Fair Value. Roosen, a prominent figure in the mining industry, is known for his leadership roles at Osisko Development Corp. and Osisko Gold Royalties.
With over 30 years of experience in developing resource ventures, Roosen’s expertise is expected to significantly contribute to Streamex’s mission of tokenizing real-world assets in the commodities market. His career highlights include the strategic development of the Canadian Malartic mine and the successful sale of Osisko Mining Corporation, which led to the creation of Osisko Royalties.
Streamex, acquired by BioSig in May 2025, operates in the digital economy, aiming to revolutionize commodity finance through blockchain technologies. While the company maintains a healthy current ratio of 2.37 and operates with moderate debt levels, InvestingPro data reveals challenges ahead with analysts anticipating sales decline in the current year. The company’s advisory board includes other notable figures such as Frank Giustra and Mathew August, each offering guidance in their respective fields of commodities and U.S. capital markets.
Henry McPhie, CEO of BioSig and Co-Founder of Streamex, praised Roosen’s track record and strategic vision, expressing enthusiasm for the direction Streamex will take under his advice. Roosen himself commented on the potential of tokenized assets to transform the resource sector and his excitement to join the company at a pivotal time.
Streamex focuses on bridging the gap between traditional finance and the digital economy, enhancing liquidity, accessibility, and efficiency in the investment landscape. The company’s infrastructure and solutions are designed to unlock new opportunities for investors and institutions worldwide.
This appointment comes at a time when the company is looking to leverage its position in the tokenized commodities space, and Roosen’s addition to the team is seen as a strategic move to bolster their expertise and industry connections. With the stock showing high price volatility and trading at elevated multiples, investors seeking deeper insights can access 14 additional exclusive ProTips and comprehensive financial analysis through InvestingPro.
The information in this article is based on a press release statement from BioSig Technologies, Inc.
In other recent news, BioSig Technologies, Inc. has regained compliance with Nasdaq’s minimum bid price requirement after its stock achieved a closing bid price of at least $1.00 per share for 10 consecutive business days. This marks a positive development following a previous notice of non-compliance. Additionally, BioSig announced its intention to merge with Streamex Exchange Corporation in an all-stock deal, aiming to integrate Streamex’s commodity-focused tokenization platform with BioSig’s operations. The merger will result in significant management changes, with Streamex’s Henry McPhie expected to become the new CEO.
In another key development, BioSig has appointed Mitch Williams as its Chief Investment Officer following the acquisition of Streamex. Williams brings over 20 years of experience in capital markets and is tasked with advancing the company’s initiatives in tokenizing real-world assets. Furthermore, BioSig has changed its independent registered public accounting firm, appointing CBIZ CPAs P.C. after Marcum LLP resigned. The company disclosed material weaknesses in internal control over financial reporting during recent fiscal years. Despite these changes, BioSig’s business operations remain unaffected by its recent Nasdaq compliance challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.